Q&A with Rob Sechrist the President of Pelorus Equity Group
The Pelorus Fund is a cannabis-focused commercial real estate mortgage REIT with a target annualized yield of 15% IRR. The Fund achieved an annualized 15.5% IRR in 2019, and the mortgage REIT qualifies for a 20% federal tax savings with monthly distributions to the Members.
OXIO’s leaders, Noel Guillama, Carl Larsen, and Gregg Steinberg have 90 years of combined experience working around a flawed healthcare system and are on track to delivering the solution as early as year-end 2020.
OXIO is the parent company of five (5) uniquely built, structured companies – all of which are designed to seamlessly work together while reducing cost, empowering patients, enabling providers and advancing the science of healthcare through “technology-infused healthcare.”
OXIO’s leaders Noel Guillama, Carl Larsen, and Gregg Steinberg have 90 years of combined experience working around a flawed healthcare system. Most recently, they have been developing several companies that intrinsically work together to improve patient quality of care, bring financial stability to physicians and advance the science of healthcare through their technology-infused healthcare model. OXIO is already proving their concept in the healthcare space and they will be taking their solution to market in Q3/Q4 2020.
xBeam 3D Metal Printing The New Industrial Revolution
xBeam 3D Metal Printing technology is a leader in The Fourth Industrial Revolution or Industry 4.0, which is driving the current transformation of traditional manufacturing and industrial practices. Industry is pressing both the pace and scale of workplace innovation to do more with less by finding simpler, less expensive, and faster ways to operate. xBeam fills that gap.
OXIO Health: Looking At Healthcare in 2030
OXIO Health, Inc. (OXIO) discusses how they are enhancing the future of healthcare. While it is clear the current system is broken, OXIO has the plan and the tools to implement an efficient and more robust system for the future.
OXIO’s leaders, Noel Guillama, Carl Larsen, and Gregg Steinberg have 90 years of combined experience working around a flawed healthcare system and are on track to delivering the solution as early as year-end 2020.
OXIO is the parent company of five (5) uniquely built, structured companies – all of which are designed to seamlessly work together while reducing cost, empowering patients, enabling providers and advancing the science of healthcare through “technology-infused healthcare.”
OXIO’s leaders Noel Guillama, Carl Larsen, and Gregg Steinberg have 90 years of combined experience working around a flawed healthcare system. Most recently, they have been developing several companies that intrinsically work together to improve patient quality of care, bring financial stability to physicians and advance the science of healthcare through their technology-infused healthcare model. OXIO is already proving their concept in the healthcare space and they will be taking their solution to market in Q3/Q4 2020.
OXIO Healthcare: Second Webinar On Fixing Healthcare in America
Hear from the management team at OXIO Health, Inc. (OXIO) as they explain their plan to empower patients, enable physicians and advance the science of healthcare that will repair the flaws in the current healthcare delivery system.
OXIO’s leaders Noel Guillama, Carl Larsen, and Gregg Steinberg have 90 years of combined experience working around a flawed healthcare system. Most recently, they have been developing several companies that intrinsically work together to improve patient quality of care, bring financial stability to physicians and advance the science of healthcare through their technology-infused healthcare model. OXIO is already proving their concept in the healthcare space and they will be taking their solution to market in Q3/Q4 2020.
Limitless Ventures: From Addiction to Recovery
Limitless Ventures combines venture and philanthropic capital to scale multi-disciplinary solutions in the lower middle market for those impacted by mental health challenges and the addiction epidemic.
During the past 3 years, our firm has raised and deployed ~$3.5m USD across 4 deals. Our team has a combined 135 years of experience across 200 transactions with some partners successfully returning over 49% Cash-on-Cash to their investors and as much as 54x EBITDA exit’s in a single transaction. Our team has over 99 years of medical expertise, and 175 years of combined addiction/recovery experience, allowing us to represent the patient, the payer, and the provider in the investment committee as we invest in deals up and down the capital structure and across the continuum of care.
Recovery Fund I is a $33m committed fund across 7 deals in 4 strategies ranging from:
Life Science Solutions ($7m)
Healthcare Technologies ($5m)
Treatment ($14m)
Long Term Recovery ($4m)
RECENT UPDATES:
Recently hired 3 new team members.
An investment today will help 500 people in the next 90 days.
All our prospective companies are performing better in the post Covid-19
Pattern Computer: Discovering New Patterns
Pattern Computer uses proprietary pattern discovery techniques to perform high-dimensional data analytics in any field with significant data complexity. The result is the delivery of breakthrough insights with demonstrable value, or what we call ‘patterndiscoveries’.
Transcending current limits of machine learning, Pattern Computer discovers previously hidden patterns in multi-dimensional data. Pattern Computer can discover higher-order correlations – going beyond pairwise / order two relationships and assessing correlations to the nth degree – without human supervision, greatly expanding the scope and depth of correlative findings.While applied first in the field of medical research, this technology can be used in virtually any industry, to uncover novel insights and transform research and business.
We are a passionate team with decades of experience in mathematics, machine learning, AI, systems architecture and visualization including a tech lead from Amazon’s “Alexa” v. 1.0 team, the co-founder of AutoDesk, an IBM Fellow and strong backgrounds in academia.
At an invite-only Department of Energy Symposium in late 2019, Pattern Computer was introduced as ‘the most advanced machine-learning company on the planet’ by Dr. James Ben Brown, Deputy Director of Environmental Genomics and Systems Biology, Lawrence Berkeley National Labs.
In March 2020, the company completed in vitro organoid testing at Lawrence Berkeley National Labs with two positive results in drug therapies that kill cancer cells but not healthy cells. Pattern is currently engaged with several labs to begin the animal testing process.
WHAT YOU WILL LEARN FROM THIS WEBINAR
The key differences between “pattern recognition” and “pattern discovery,” why they matter, and a comparison between current AI/ML practices and our Pattern Discovery Engine™
What puts Pattern Computer ahead of other global companies such as Ayasdi, IBM (Watson), Palantir and more, including size of runs and complexity of data and solutions.
Which industries can benefit from our system, and major discoveries this new system has made to date, in bio, aerospace manufacturing, flight operations, new materials, animal medicine. New tools in visualization, both for customer communications and internal research.
How Family Offices and Angels can become involved in an opportunity in the future of making important new discoveries any field, unlocking business advantage and life-saving solutions.
IndexIQ: The Next Frontier of Institutional Investing
A subsidiary of one of the oldest and largest life insurance companies in the world, we have a solid foundation and the resources to continue our culture of innovation.
Institutional Investors increasingly using Liquid Alt ETFs for both strategic and tactical allocations
The recent launch of our ESG-related ETFs in partnership with fellow NYLI boutique CANDRIAM.
The growing popularity among investors of actively managed ETFs, particularly actively managed Municipals and High Yield Low Volatility.
The ETF structure will continue to grow across all investor types, from self-directed retail to the largest institutional manager, due to the structural efficiencies’ ETFs provide and the consistently expanding menu of exposure options. Equities have been the dominant asset class in ETFs thus far, but as the ETF ecosystem grows, the smaller areas will increase at an accelerated pace, particularly liquid alternatives, and actively managed exposures, that generate alpha.
IndexIQ has established a long track record of demonstrating the value of innovation. From offering the first liquid alternative ETF, to leveraging our multi-boutique platform, each ETF is thoughtfully- constructed and our specialized investment solutions help our clients meet the increasingly complex challenges they face in their portfolios today. We provide leading solutions in three categories – liquid alternatives, smart core solutions, and actively managed strategies leveraging our larger multi-boutique structure.
BACKGROUND
After managing the venture portfolio for Oracle, Eric Ball and Jack Crawford spun out to launch Impact Venture Capital in 2016.
Impact Venture Capital differentiates through its strong partnerships with corporate venture groups of the world’s largest companies. Through these partnerships, the innovative VC firm is able to bring additional capital, customers, and credibility to the startups they invest in.
Impact Venture Capital has now co-invested alongside Intel, Baidu, Yamaha, SK Hynix, Kubota, Goldman Sachs and other leading corporations into 17 companies that have raised more than $200M of follow-on investments.
In Impact Venture Capital’s Fund I, 8 companies have already increased in value and one was acquired in March by Thomson Reuters for $125M.
Following a $10M initial close from existing LPs, Impact Venture Capital is now working to identify additional family offices and corporations for its targeted $50M Fund II in 2020.
Impact has made three investments already from Fund II: Syntegra (digital health), ScoreData (predictive analytics), and CapConnect+ (bond issuance platform), and will make more throughout the year.
WHAT YOU WILL LEARN FROM THIS WEBINAR
Early-stage venture is an independent asset class, offering diversification and the best risk-return history of any asset class
Why 2020 is an unusually good year to invest in early-stage venture
How Impact Venture Capital’s corporate partnerships and domain expertise (around artificial intelligence, high performance computing, drones, robotics, and healthcare technology) are creating superior investment opportunities
What co-investment opportunities exist for family offices in the Impact Venture Capital investor base
Where to go to learn more
OXIO Health: Healthcare Post COVID – The New Paradigm, an Opportunity
Company: OXIO is disrupting the healthcare industry with a multifaceted approach to correct the complex flaws across the industry, from billing to patient care and physician motivation
Invested: $8 million designing and building a fully operational (SaaS model) and certified ambulatory electronic medical records platform.
Team: Seasoned leadership with more than 30 years in healthcare, practice management, patient care, technology, real estate & construction, with multiple companies taken public and successful exits.
Vision: To change use of technology and systems in healthcare delivery to improve quality of care and reduce the cost of healthcare
Intellectual Property: 39 issued and pending patents licensed, along with other proven technologies.
Distributive Venture Platform SM (“DVP”) Portfolio Companies: Fully operational Electronic Medical Record, Disease and Medical Practice Management company, Personal Wellness Blockchain Record company, Healthcare IoT/Wearable Device company, Medical Practice Acquisition and Managed Services Organization, Real Estate Shared Medical Facilities company
Technology Leverage: Patient Care Management, Remote Patient Monitoring, Telemedicine, Predictive Analytics, Machine Learning, Augmented Reality and Artificial Intelligence.
Diversified Risk: Our DVP aggregates the cross-company leveraging of product(s) or service(s) yielding a unique and strong value proposition while ensuring a wide range of risk tolerance and market penetration.
What you will learn from this webinar?
Problems in the U.S. Healthcare Delivery System That Are Creating a Looming Crisis
Solutions: 5 (initial) Solutions to the U.S. Healthcare Crisis
A New Business Model: Distributive Venture Platform with Diversified Risk
Future of Healthcare: “Technology-Infused Healthcare”
Opportunity: to make an investment that yields measurable, beneficial social impact alongside a healthy financial return
Impact Venture Capital: Early-Stage Technology Venture Investment Opportunity for Family Offices
Impact Venture Capital is a Silicon Valley-based venture capital firm that invests alongside family offices and corporate venture groups into high growth technology startups.
BACKGROUND
After managing the venture portfolio for Oracle, Eric Ball and Jack Crawford spun out to launch Impact Venture Capital in 2016.
Impact Venture Capital differentiates through its strong partnerships with corporate venture groups of the world’s largest companies. Through these partnerships, the innovative VC firm is able to bring additional capital, customers, and credibility to the startups they invest in.
Impact Venture Capital has now co-invested alongside Intel, Baidu, Yamaha, SK Hynix, Kubota, Goldman Sachs and other leading corporations into 17 companies that have raised more than $200M of follow-on investments.
In Impact Venture Capital’s Fund I, 8 companies have already increased in value and one was acquired in March by Thomson Reuters for $125M.
Following a $10M initial close from existing LPs, Impact Venture Capital is now working to identify additional family offices and corporations for its targeted $50M Fund II in 2020.
Impact has made three investments already from Fund II: Syntegra (digital health), ScoreData (predictive analytics), and CapConnect+ (bond issuance platform), and will make more throughout the year.
WHAT YOU WILL LEARN FROM THIS WEBINAR
Early-stage venture is an independent asset class, offering diversification and the best risk-return history of any asset class
Why 2020 is an unusually good year to invest in early-stage venture
How Impact Venture Capital’s corporate partnerships and domain expertise (around artificial intelligence, high performance computing, drones, robotics, and healthcare technology) are creating superior investment opportunities
What co-investment opportunities exist for family offices in the Impact Venture Capital investor base
Where to go to learn more
Akamara Therapeutics: Reimagining Immunotherapy for Cancer & Rare Disease
Novel scientific insights to unlock the full potential of B cell therapeutics
Range of treatment opportunities for cancer immunotherapy and B cell-driven rare diseases
Lead program, AT-1965, advancing toward IND and initiation of solid tumor clinical study in 2H2020
Positive pre-IND interaction with FDA; alignment on 2020 IND submission and clinical initiation for AT-1965
Collaborative team with leadership across all biotech disciplines; premier scientific advisors and leading entrepreneur backers
Financing underway to fund AT-1965 clinical initiation and development
What You Will Learn From This Webinar
The importance of B Cells role in cancer immunotherapy
Why AT-1965 is Poised to Lead the Next Frontier in Cancer Immunotherapy
How our Phase 1 Study Design Provides a Strong Opportunity to Detect Clinical Activity in Cancer Patients
How Reimagining Immunotherapy Will Move B Cell Treatments Beyond the Limits of History